This is an aggregated industry headline. Read the full story at FiercePharma →
Apollo inks €3B equity deal for stake in Bayer's contraceptives business
Bayer has addressed its need for a capital infusion under a deal to secure 3 billion euros ($3.4 billion) in equity from New York City asset manager Apollo, surrendering a minority, non-controlling stake in its newly established long-acting reversible contraceptives business.
By FiercePharma
· Jul 12, 2026
· via FiercePharma
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlineFiercePharma
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFierceBiotech ↗
KKR, the global investment giant, has launched Allyntra as a new, precision-engineered solutions platform for …
The WeekBriefing
The FDA has expanded the use of the Padcev-Keytruda combination in bladder cancer, intensifying competition fo…
The WeekFiercePharma ↗
Fierce Pharma is launching the weekly Oral GLP-1 Tracker, leveraging analysts' notes and IQVIA data to monitor…